Laidlaw analyst Yale Jen downgraded Evofem to Hold from Buy after the company said it will be acquired by Aditxt. The firm said that the $100M valuation is “good” for Evofem shareholders with likely upside going forward for the value of Phexxi. Laidlaw added that the firm vies the deal as a potentially “win-win” transaction for both companies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EVFM:
